Overview

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

Status:
Completed
Trial end date:
2021-01-19
Target enrollment:
Participant gender:
Summary
This study will be a 2-period study conducted with 14 healthy male or female subjects. Subjects will be administered surufatinib alone in Period 1 and in combination with itraconazole in Period 2.
Phase:
Phase 1
Details
Lead Sponsor:
Hutchison Medipharma Limited
Treatments:
Itraconazole